

The Manager
Companies Announcement Platform
SIM Venture Securities Exchange

3 July 2012

Serum Institute of India Orders 500,000 SoloFlow[®] Cannula

HIGHLIGHTS:

- **500,000 SoloFlow[®] Transfer Cannula ordered by Serum Institute of India ("SII") – the second order for SII**
-

The Board of Telezon[®] Limited ("the Company") is pleased to announce that following the placement and successful review of 28,600 SoloFlow[®] needles, the Serum Institute of India, the world's largest producer of Measles and DTP vaccines, has placed a second commercial order for 500,000 SoloFlow[®] needles for market use.

This second commercial order demonstrates both confidence in the SoloFlow[®] needle and our Company, and consolidates the next stage in our working relationship with SII.

For more information about SII, refer to <http://www.seruminstitute.com/>

For and on behalf of Telezon Limited,

Dr Michelle Carr
Director & Co. Secretary
T: 61 03 9763 8605 F: 61 03 9763 2714